Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Genzyme Revises Fabrazyme Phase IV Proposal In Bid For April Approval

Executive Summary

Genzyme's proposal for completing its Phase IV Fabrazyme study is the kind of innovative drug development proposal that FDA Commissioner McClellan is encouraging, Genzyme CEO Henri Termeer suggested during a March 5 conference call

You may also be interested in...



The Mark Of McClellan? Commissioner Downplays Role In Drug Approvals

FDA Commissioner McClellan's direct contribution to product reviews is limited to drawing on a network of outside experts to assist in decisions, the commissioner suggested during a May 16 Manhattan Institute-sponsored roundtable with buy-side analysts

The Mark Of McClellan? Commissioner Downplays Role In Drug Approvals

FDA Commissioner McClellan's direct contribution to product reviews is limited to drawing on a network of outside experts to assist in decisions, the commissioner suggested during a May 16 Manhattan Institute-sponsored roundtable with buy-side analysts

Fabrazyme Approved; FDA Weighing What Confirmatory Data Will Be Needed

FDA has set a deadline of Jan. 31, 2004 for Genzyme's Fabrazyme confirmatory placebo-controlled trial following its April 24 approval

Related Content

UsernamePublicRestriction

Register

PS041394

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel